Extended-release lovastatin effectively and safely lowers LDL cholesterol in patients with Alzheimer’s disease, researchers reported at the American College of Clinical Pharmacology (ACCP).
“The take home message here is that this statin in its extended-release formulation is safe and effective for treatment of patients with Alzheimer’s Disease,” said researcher Arnold Sterman, Ph.D, executive director of medical affairs and safety at Andrx Labs in Hackensack, New Jersey, who presented the findings here Sept. 22nd.
Altocor has been approved by the FDA as a once-daily adjunct to diet for the reduction of elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, and to increase levels of high-density lipoprotein cholesterol (HDL-C) in those with primary hypercholesterolemia. Altocor is also indicated to slow the progression of coronary atherosclerosis in patients with coronary artery disease, as part of a cholesterol-lowering treatment strategy.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!